Johnson & Johnson has acquired Firefly Bio and its degrader antibody conjugate platform technology for $1 billion in cash, according to a June 8 announcement. The California-based biotech's approach merges the science of antibody drug conjugates and protein degraders, aiming to deliver selective protein degraders directly to tumor cells while sparing healthy tissue.
The acquisition is intended to help Johnson & Johnson use Firefly's preclinical degrader antibody conjugate (DAC) platform specifically for KRAS-driven tumors, which are often challenging to treat. John Reed, executive vice president of innovative medicine and research and development at Johnson & Johnson, said in a statement, “KRAS has notoriously been considered an undruggable target, and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years. We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors.”
Firefly Bio first gained attention in 2024 when it launched with $94 million in funding from founding investor Versant Ventures as well as MPM BioImpact, Decheng Capital, and Eli Lilly. The company was co-founded by Nobel prize winner and Stanford professor Carolyn Bertozzi.
The acquisition comes amid increased activity in the KRAS inhibitor space following Revolution Medicines’ RAS inhibitor daraxonrasib doubling pancreatic cancer survival rates compared to chemotherapy earlier this year. On Monday, Revolution Medicines and partner Tango Therapeutics reported that their combination approach achieved a 92% response rate among 12 patients with pancreatic cancer—a higher response than either therapy alone or combined with chemotherapy.
In related deals within the sector, Roche recently paid $700 million upfront for rights to Nurix Therapeutics’ protein degrader bexobrutideg. In April, Roche also committed up to $1 billion more to expand an ongoing partnership with C4 Therapeutics involving two additional DACs.
